Neurocrine Biosciences (NBIX) Asset Utilization Ratio (2011 - 2026)

Neurocrine Biosciences (NBIX) has reported Asset Utilization Ratio for 16 consecutive years, with 0.66 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Asset Utilization Ratio fell 0.77% year-over-year to 0.66; the trailing twelve-month figure through Jun 2026 stood at 0.66 (down 0.77% YoY), and the FY2025 full-year result was 0.69, up 1.38% from the prior year.
• Asset Utilization Ratio grew to 0.66 in Q2 2026 per NBIX's latest filing, from 0.65 in the prior quarter.
• Across five years, Asset Utilization Ratio topped out at 0.68 in Q1 2023 and bottomed at 0.57 in Q1 2022.
• Historically, Asset Utilization Ratio has averaged 0.64 across 5 years, with a median of 0.65 in 2023.
• The sharpest annual moves came in 2022 and 2024: Asset Utilization Ratio rose 24.37% in 2022, then decreased 12.8% in 2024.
• Over 5 years, Asset Utilization Ratio stood at 0.66 in 2022, then fell by 6.23% to 0.62 in 2023, then grew by 4.95% to 0.65 in 2024, then decreased by 0.98% to 0.64 in 2025, then advanced by 2.23% to 0.66 in 2026.
• According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.66, 0.65, and 0.64 for Q2 2026, Q1 2026, and Q4 2025 respectively.